ArticleClinical rheumatology2021

Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.

Cosimo Bruni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.